Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
Interventions
NT-501, Sham
Drug · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Alzheimer Disease
Interventions
Human Nerve Growth Factor
Genetic
Lead sponsor
The Shiley Family Trust
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
La Jolla, California
Conditions
Growth Hormone Deficiency
Interventions
VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Retinitis Pigmentosa
Interventions
Low Dose NT-501, High Dose NT-501
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 68 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Conditions
Persistent Corneal Epithelial Defect
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more
Completed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Study of Exercise and Memory Function

NCT02057354
Conditions
Aging
Interventions
Aerobic Exercise, Non-Aerobic Exercise
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neurotrophic Keratitis
Interventions
KB801, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
Conditions
MacTel (Macular Telangiectasia) Type 2
Interventions
Ciliary neurotrophic factor (CNTF), Surgery
Biological · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
Conditions
Corneal Disease, Neuropathy
Interventions
Cenegermin-Bkbj
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501/revakinagene taroretcel-lwey
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Charcot-Marie-Tooth Neuropathy Type 1A
Interventions
scAAV1.tMCK.NTF3
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation

NCT02911805
Conditions
Vision Disorders
Interventions
Aerobic exercise, Balance exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
50 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more
Conditions
Dry Eye
Interventions
Oxervate, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more
Conditions
Progressive Supranuclear Palsy
Interventions
GDNF & Synchro Med Infusion System
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
37
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 29 more
Conditions
HIV Infections, Peripheral Nervous System Disease
Interventions
Nerve Growth Factor, Recombinant Human
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
14
States / cities
Los Angeles, California • San Mateo, California • Stanford, California + 10 more
Conditions
Retinitis Pigmentosa
Interventions
NT-501
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
Conditions
Retinitis Pigmentosa
Interventions
Ciliary Neurotrophic Factor Implant NT-501
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more